EP 0856052 A1 19980805 - ANTISENSE OLIGONUCLEOTIDE CHEMOTHERAPY FOR BENIGN HYPERPLASIA OR CANCER OF THE PROSTATE
Title (en)
ANTISENSE OLIGONUCLEOTIDE CHEMOTHERAPY FOR BENIGN HYPERPLASIA OR CANCER OF THE PROSTATE
Title (de)
CHEMOTHERAPIE MIT ANTISENSE-OLIGONUKLEOTIDEN ZUR BEHANDLUNG VON GUTARTIGER HYPERPLASIE ODER PROSTATAKREBS
Title (fr)
CHIMIOTHERAPIE PAR LES OLIGONUCLEOTIDES ANTISENS DE L'HYPERPLASIE OU DU CANCER DE LA PROSTATE
Publication
Application
Priority
- US 9615123 W 19960920
- US 404495 P 19950920
Abstract (en)
[origin: WO9711172A1] Methods of selectively inhibiting the growth of or killing prostatic cells, using antisense oligonucleotides to prostate specific genes, are disclosed. The oligonucleotides may have natural nucleic acid structures or may be modified oligonucleotides with enhanced stability or tissue specific targeting. The prostate specific genes to which the antisense may be directed include the PSA and the probasin gene. Pharmaceutical compositions including such antisense oligonucleotides are also described for use in the methods. The methods and products are of particular utility in the treatment of benign prostatic hyperplasia or prostate cancer.
IPC 1-7
IPC 8 full level
C12N 15/113 (2010.01); A61K 38/00 (2006.01)
CPC (source: EP)
C12N 15/1137 (2013.01); C12Y 113/11012 (2013.01); A61K 38/00 (2013.01); C12N 2310/315 (2013.01); C12N 2310/351 (2013.01); C12N 2310/53 (2013.01)
Citation (search report)
See references of WO 9711172A1
Designated contracting state (EPC)
DE FR GB IT
DOCDB simple family (publication)
WO 9711172 A1 19970327; AU 7077596 A 19970409; CA 2232390 A1 19970327; EP 0856052 A1 19980805
DOCDB simple family (application)
US 9615123 W 19960920; AU 7077596 A 19960920; CA 2232390 A 19960920; EP 96931664 A 19960920